A novel signature of two long non-coding RNAs in BRCA mutant ovarian cancer to predict prognosis and efficiency of chemotherapy.
A novel signature of two long non-coding RNAs in BRCA mutant ovarian cancer to predict prognosis and efficiency of chemotherapy.
复制标题
BRCA突变卵巢癌中两个长非编码RNA的新特征预测预后和化疗效率
DOI：
10.1186/s13048-020-00712-w
复制
发表时间：
2020-09-19
影响因子：
4
通讯作者：
Deng Q
中科院分区：
文献类型：
--
作者：
Pan Y;Jia LP;Liu Y;Han Y;Li Q;Zou Q;Zhang Z;Huang J;Deng Q
在这项研究中，我们的目的是确定BRCA 1/2突变的预后标志，以预测疾病进展和化疗卵巢癌（OV）的效率，卵巢癌是全球女性妇科癌症死亡的第二大常见原因。单变量考克斯比例风险和多变量考克斯回归分析用于从癌症基因组图谱（TCGA）数据库获得的数据中识别预后因素。评估受试者工作特征曲线的曲线下面积，并确定预测模型的灵敏度和特异性。选择由两个长非编码RNA（lncRNA）Z98885.2和AC011601.1组成的签名作为将患者分为高风险组和低风险组的基础（中位生存期：7.2年vs 2.3年）。高风险组和低风险组的3年总生存率（OS）分别约为38%和100%。化疗治疗生存率表明，高危组辅助化疗的OS率显著低于低危组。高危组的1年、3年和5年OS分别为100%、40%和15%。高危组经OV化疗2年后生存率迅速下降。多因素考克斯回归分析显示2-lncRNA模型可作为卵巢癌的独立预后因素。对来自京都基因和基因组百科全书（KEGG）和基因本体论（GO）的数据的分析表明，这些特征对癌症的发展至关重要。总之，Z98885.2和AC011601.1构成了携带BRCA 1/2突变的OV患者的新预后标志，并且可用于预测预后和化疗的效率。
In this study we aimed to identify a prognostic signature in BRCA1/2 mutations to predict disease progression and the efficiency of chemotherapy ovarian cancer (OV), the second most common cause of death from gynecologic cancer in women worldwide. Univariate Cox proportional-hazards and multivariate Cox regression analyses were used to identifying prognostic factors from data obtained from The Cancer Genome Atlas (TCGA) database. The area under the curve of the receiver operating characteristic curve was assessed, and the sensitivity and specificity of the prediction model were determined. A signature consisting of two long noncoding RNAs(lncRNAs), Z98885.2 and AC011601.1, was selected as the basis for classifying patients into high and low-risk groups (median survival: 7.2 years vs. 2.3 years). The three-year overall survival (OS) rates for the high- and low-risk group were approximately 38 and 100%, respectively. Chemotherapy treatment survival rates indicated that the high-risk group had significantly lower OS rates with adjuvant chemotherapy than the low-risk group. The one-, three-, and five-year OS were 100, 40, and 15% respectively in the high-risk group. The survival rate of the high-risk group declined rapidly after 2 years of OV chemotherapy treatment. Multivariate Cox regression associated with other traditional clinical factors showed that the 2-lncRNA model could be used as an independent OV prognostic factor. Analyses of data from the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) indicated that these signatures are pivotal to cancer development. In conclusion, Z98885.2 and AC011601.1 comprise a novel prognostic signature for OV patients with BRCA1/2 mutations, and can be used to predict prognosis and the efficiency of chemotherapy.
登录
查看更多内容
影响因子：
--
作者：
Meng X;Jin-Cheng G;Jue Z;Quan-Fu M;Bin Y;Xu-Feng W
通讯作者：
Xu-Feng W
影响因子：
2.7
作者：
Kawaguchi T;Azuma K;Sano M;Kim S;Kawahara Y;Sano Y;Shimodaira T;Ishibashi K;Miyaji T;Basch E;Yamaguchi T
通讯作者：
Yamaguchi T
DOI：
10.1038/nrm.2017.104
发表时间：
2018-03
期刊：
Nature reviews. Molecular cell biology
影响因子：
--
作者：
Ransohoff JD;Wei Y;Khavari PA
通讯作者：
Khavari PA
影响因子：
7.3
作者：
Foulkes, William D.;Shuen, Andrew Y.
通讯作者：
Shuen, Andrew Y.
影响因子：
5.6
作者：
Okoye, Ekene;Euscher, Elizabeth D.;Malpica, Anais
通讯作者：
Malpica, Anais